polatuzumab vedotin news

All news on polatuzumab vedotin (also known as Polivy, polatuzumab vedotin (genetical recombination), and polatuzumab vedotin-piiq): plants, production capacities, investments and involved companies.

17 September 2026

Roche: Lunsumio plus lenalidomide improves PFS in relapsed/refractory follicular lymphoma

Phase III CELESTIMO interim analysis showed a statistically significant, clinically meaningful PFS benefit versus rituximab+lenalidomide; OS immature; safety consistent with known profiles.
16 September 2026

Genentech: Lunsumio plus lenalidomide improves PFS in Phase III CELESTIMO for relapsed/refractory follicular lymphoma

Phase III CELESTIMO showed a statistically significant, clinically meaningful progression‑free survival benefit for Lunsumio plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory FL after ≥1 prior therapy.
18 June 2026

Roche: FDA accepts sBLA for subcutaneous Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted based on phase III SUNMO showing 59% reduction in progression risk; FDA decision expected by 9 Feb 2027.
17 June 2026

Genentech seeks FDA approval for Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
24 April 2026

Chugai Q1 FY2026 Results

Core rev ¥321.7B (+11.5%), core OP ¥163.3B (+17.1%), core net ¥118.6B (+19.6%). Launched Elevidys (DMD JP); Lunsumio+Polivy approved for LBCL. R&D: NXT007 switch, Enspryng (MOGAD), Foundayo US approval.
23 March 2026

Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma

Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.

Who will be producing polatuzumab vedotin in the future?

Find out with chemXplore Alpha

Learn more